Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
Sponsor
University of Wisconsin, Madison (Other)
Overall Status
Completed
CT.gov ID
NCT00214058
Collaborator
Aventis Pharmaceuticals (Industry)
36
1
42.1
0.9
Study Details
Study Description
Brief Summary
The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma
Study Start Date
:
Aug 1, 2002
Actual Study Completion Date
:
Feb 1, 2006
Outcome Measures
Primary Outcome Measures
- Safety and Efficacy []
Secondary Outcome Measures
- QOL []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
Female
Inclusion Criteria:
- Recurrent ovarian or peritoneal cancer
Exclusion Criteria:
- No prior chemotherapy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Wisconsin Hospital and Clinics | Madison | Wisconsin | United States | 53792 |
Sponsors and Collaborators
- University of Wisconsin, Madison
- Aventis Pharmaceuticals
Investigators
- Principal Investigator: David M Kushner, MD, University of Wisconsin, Madison
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.Responsible Party:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00214058
Other Study ID Numbers:
- CO02701
- 2002-224
- A532820
- SMPH/OBSTET & GYNECOL
First Posted:
Sep 21, 2005
Last Update Posted:
Nov 19, 2019
Last Verified:
Jun 1, 2008
Additional relevant MeSH terms: